Quantification of the contribution of GLP-1 to mediating insulinotropic effects of DPP-4 inhibition with vildagliptin in healthy subjects and patients with type 2 diabetes using exendin [9-39] as a GLP-1 receptor antagonist

Diabetes

Volumn 65, Issue 8, 2016, Pages 2440-2447

  Nauck, Michael A ^a,b   Kind, Joachim ^c   Köthe, Lars D ^a   Holst, Jens J ^d   Deacon, Carolyn F ^d   Broschag, Matthias ^c   He, Yan Ling ^e   Kjems, Lise ^e   Foley, James ^f  

^a DIABETESZENTRUM BAD LAUTERBERG   (Germany)

^b ST JOSEF HOSPITAL   (Germany)

^c PAREXEL INTERNATIONAL   (United States)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^f NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCOSE; INSULIN; METFORMIN; PLACEBO; VILDAGLIPTIN; ADAMANTANE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN (9-39); GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE BLOOD LEVEL; NITRILE; PEPTIDE FRAGMENT; PYRROLIDINE DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; AREA UNDER THE CURVE RATIO; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; DRUG MEGADOSE; ENZYME INHIBITION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN LIKE ACTIVITY; INSULIN RELEASE; MALE; MEDIATOR; NON INSULIN DEPENDENT DIABETES MELLITUS; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH EMPTYING; TEST MEAL; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; METABOLISM; MIDDLE AGED; NORMAL HUMAN;

ADAMANTANE; ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; GASTRIC EMPTYING; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HEALTHY VOLUNTEERS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; NITRILES; PEPTIDE FRAGMENTS; PYRROLIDINES;

EID: 84980367633     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db16-0107     Document Type: Article

References (27)

1. Ahrén B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004;89: 2078-2084
2. Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006;91:4612-4619
3. Krarup T, Saurbrey N, Moody AJ, Kühl C, Madsbad S. Effect of porcine gastric inhibitory polypeptide on β-cell function in type I and type II diabetes mellitus. Metabolism 1987;36:677-682
4. Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993;91:301-307
5. Vilsbøll T, Krarup T, Madsbad S, Holst JJ. Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia 2002;45:1111-1119
6. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 1999;85:9-24
7. Nauck MA, El-Ouaghlidi A. The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1. Diabetologia 2005;48:608-611
8. Holst JJ, Deacon CF. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia 2005;48:612-615
9. Göke R, Fehmann HC, Linn T, et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 1993;268: 19650-19655
10. Thorens B, Porret A, Bühler L, Deng SP, Morel P, Widmann C. Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 1993;42:1678-1682
11. Schirra J, Sturm K, Leicht P, Arnold R, Göke B, Katschinski M. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans. J Clin Invest 1998;101:1421-1430
12. Edwards CMB, Todd JF, Mahmoudi M, et al. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes 1999;48:86-93
13. Aulinger BA, Bedorf A, Kutscherauer G, et al. Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade. Diabetes 2014;63:1079-1092
14. Carr RD, Larsen MO, Jelic K, et al. Secretion and dipeptidyl peptidase-4-mediated metabolism of incretin hormones after a mixed meal or glucose ingestion in obese compared to lean, nondiabetic men. J Clin Endocrinol Metab 2010;95:872-878
15. Lartigue S, Bizais Y, Des Varannes SB, Murat A, Pouliquen B, Galmiche JP. Inter- and intrasubject variability of solid and liquid gastric emptying parameters. A scintigraphic study in healthy subjects and diabetic patients. Dig Dis Sci 1994; 39:109-115
16. Schvarcz E, Palmér M, Aman J, Horowitz M, Stridsberg M, Berne C. Physiological hyperglycemia slows gastric emptying in normal subjects and patients with insulin-dependent diabetes mellitus. Gastroenterology 1997;113:60-66
17. Nauck MA, Kind J, Deacon CF, et al. Blocking GLP-1 action with exendin [9-39] to determine the contribution of GLP-1 to the insulinotropic effects of the DPP-4 inhibitor vildagliptin (Abstract). Diabetologia 2011;54(Suppl. 1):S108
18. Vardarli I, Arndt E, Deacon CF, Holst JJ, Nauck MA. Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and "isoglycemic" intravenous glucose. Diabetes 2014;63:663-674
19. El-Ouaghlidi A, Rehring E, Holst JJ, et al. The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion. J Clin Endocrinol Metab 2007;92:4165-4171
20. Kielgast U, Asmar M, Madsbad S, Holst JJ. Effect of glucagon-like peptide-1 on alpha- and beta-cell function in C-peptide-negative type 1 diabetic patients. J Clin Endocrinol Metab 2010;95:2492-2496
21. Hovorka R, Soons PA, Young MA. ISEC: a program to calculate insulin secretion. Comput Methods Programs Biomed 1996;50:253-264
22. Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ. Secretion of glucagonlike peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia 2011;54:10-18
23. Deane AM, Nguyen NQ, Stevens JE, et al. Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia. J Clin Endocrinol Metab 2010;95:215-221
24. Aaboe K, Knop FK, Vilsbøll T, et al. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2010;12:323-333
25. Maida A, Lovshin JA, Baggio LL, Drucker DJ. The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances beta-cell function but does not inhibit gastric emptying in mice. Endocrinology 2008;149:5670-5678
26. Filipsson K, Sundler F, Ahrén B. PACAP is an islet neuropeptide which contributes to glucose-stimulated insulin secretion. Biochem Biophys Res Commun 1999;256:664-667
27. Humpert PM, Neuwirth R, Battista MJ, et al. SDF-1 genotype influences insulin-dependent mobilization of adult progenitor cells in type 2 diabetes. Diabetes Care 2005;28:934-936